Antimetabolite cancer drug gemcitabine selectively impacts preantral and antral follicle cohorts in the ovary as evidenced by quantitatively histomorphometric, hormonal and cell viability markers

2024-11-0920140268-1161N/Ahttps://hdl.handle.net/20.500.14288/11806N/AObstetricsGynecologyReproductive biologyAntimetabolite cancer drug gemcitabine selectively impacts preantral and antral follicle cohorts in the ovary as evidenced by quantitatively histomorphometric, hormonal and cell viability markersMeeting Abstract1460-235035974530039310200